Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Takeda taps Wave for antisense compounds
by Ryan Cross
February 26, 2018
| A version of this story appeared in
Volume 96, Issue 9
Takeda Pharmaceutical is partnering with Wave Life Sciences to develop antisense nucleic acid therapies to treat neurological conditions such as Huntington’s disease and amyotrophic lateral sclerosis. Takeda will pay $110 million in cash to Wave, purchase $60 million of Wave’s shares, and provide $60 million or more in research funding over four years. Wave’s oligonucleotides are designed to block the production of proteins that cause disease. The Harvard chemist and serial entrepreneur Gregory Verdine was one of Wave’s cofounders.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter